Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies.

JCO oncology practice·2024
Same author

Patient Perception of Telehealth Services for Breast and Gynecologic Oncology Care during the COVID-19 Pandemic: A Single Center Survey-based Study.

Journal of breast cancer·2020
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 2, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.

Brittney S Zimmerman1,2, Francisco J Esteva1,2

  • 1Northwell, New Hyde Park, NY 11042, USA.

Cancers
|February 24, 2024
PubMed
Summary
This summary is machine-generated.

New antibody-drug conjugates (ADCs) offer precise HER2-targeted therapy for breast cancer. These advanced treatments aim to improve outcomes for patients with HER2-positive and HER2-Low disease.

Keywords:
HER2antibody–drug conjugatesbreast neoplasmsdrug resistancetargeted therapytrastuzumab deruxtecantrastuzumab-DM1

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.7K
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.0K

Related Experiment Videos

Last Updated: Jul 2, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.7K
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.0K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast cancers, correlating with poorer prognosis.
  • Traditional treatments involve chemotherapy and HER2-targeted monoclonal antibodies (e.g., trastuzumab, pertuzumab).

Purpose of the Study:

  • To review the current status of HER2-targeted antibody-drug conjugates (ADCs) in breast cancer treatment.
  • To discuss emerging investigational HER2-targeted ADCs and their potential impact.

Main Methods:

  • Review of current literature and clinical trial data on HER2-targeted ADCs.
  • Analysis of the structure, mechanism, and clinical application of ADCs like trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd).

Main Results:

  • HER2-targeted ADCs, such as T-DM1 and T-DXd, represent a novel therapeutic class combining monoclonal antibodies with cytotoxic payloads.
  • Ongoing research focuses on novel combinations and sequential approaches to overcome resistance to existing ADCs.
  • New ADCs are being developed for greater precision and reduced toxicity in HER2-targeted therapy.

Conclusions:

  • HER2-targeted ADCs are revolutionizing breast cancer treatment, offering improved precision and potentially better outcomes.
  • Clinical trials are essential for optimizing dosing, understanding resistance, and identifying patient subgroups benefiting most from these therapies.
  • These advanced ADCs hold significant promise for both HER2-positive and HER2-Low breast cancer patients.